<DOC>
	<DOC>NCT02409355</DOC>
	<brief_summary>This randomized, open-label study is designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in participants with chemotherapy-naive, Stage IV squamous NSCLC.</brief_summary>
	<brief_title>A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically or cytologically confirmed Stage IV squamous NSCLC Tumor programmed deathligand 1 (PDL1) expression, as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening No prior treatment for Stage IV squamous NSCLC Measurable disease as defined by RECIST v1.1 Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Adequate hematologic and endorgan function Active or untreated central nervous system (CNS) metastases Untreated or inadequately treated spinal cord compression Leptomeningeal disease Uncontrolled pleural effusion, pericardial effusion, or ascites Uncontrolled tumorrelated pain Uncontrolled hypercalcemia Any other malignancies within 5 years except those with negligible risk of metastasis or death Pregnant or lactating women Known hypersensitivity to any component of atezolizumab formulation or other study medication History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes Prior allogeneic bone marrow or solid organ transplantation Positive human immunodeficiency virus (HIV) test Active hepatitis B or C Active tuberculosis Significant cardiovascular disease Severe infection or major surgery within 4 weeks prior to randomization Use of any approved anticancer therapy within 3 weeks prior to treatment Use of an investigational agent or participation in another clinical trial within 4 weeks prior to randomization Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4 weeks prior to randomization Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, antiprogrammed death1 (antiPD1), and antiPDL1 therapeutic antibodies Treatment with immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>